Policy challenges of nanomedicine for Australia's PBS
All major pharmaceutical companies are currently investing significantly in the development of medicines with a nanotechnology component. Such research promises therapeutic drugs with greater efficacy and a wider range of clinical indications. Nanomedicines are just beginning to enter drug regulatory processes, but within a few decades could comprise a dominant group within the class of innovative pharmaceuticals. The current thinking of government safety and cost-effectiveness regulators...[Show more]
|Collections||ANU Research Publications|
|Source:||Australian Health Review|
|01_Faunce_Policy_challenges_of_2009.pdf||217.31 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.